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Artesunate–meﬂ oquine: a malaria treatment for 
African children?
Artesunate–meﬂ oquine is one of ﬁ ve artemisinin-based 
combination therapy (ACT) formulations recommended 
by WHO for the treatment of uncomplicated falciparum 
malaria worldwide.1 The scaled-up deployment of ACTs 
in Africa during the past 10 years, and their substitution 
in place of failing monotherapies, particularly chloro-
quine and sulfadoxine–pyrimethamine, has con tributed 
to the reduction in levels of malaria trans mission,2 
and currently, no other therapy is as eﬀ ective. The 
artemisinin component has a short-lived but powerful 
action to reduce the malaria parasite count, reducing 
the chance of severe disease and death and onward 
transmission of the infection. The partner antimalarial 
drug has a slower elimination half-life, producing a 
post-treatment prophylactic eﬀ ect, which conveys 
additional beneﬁ t in high-endemic settings. Alarmingly, 
the emergence of artemisinin-tolerant parasites in 
south-east Asia is now well documented. One strategy 
to prevent the spread of artemisinin resistance is to have 
a range of ACT formulations available for use in a given 
setting, so that the parasite population is not over-
exposed to the pressure of any single drug combination.1
Despite its recommendation for use in Africa, 
artesunate–meﬂ oquine is absent from treatment guide-
lines and unregistered in many African countries. Policy 
makers need to be sure that their decisions regarding 
drug deployment are well informed. Extensive use of 
artesunate–meﬂ oquine and meﬂ oquine monotherapy, 
mainly in southeast Asia, has shown that notable 
drug-attributed eﬀ ects are early vomiting, during the 
treatment course, and self-limiting neuro psychiatric 
eﬀ ects, most commonly dizziness and insomnia.3–7 
Concerns about a paucity of data on tolerance and 
eﬃ  cacy of artesunate–meﬂ oquine in children, who carry 
the greatest burden of malaria cases in Africa, might 
contribute to the rarity of its use.
In The Lancet Infectious Diseases, Sodiomon Sirima 
and colleagues8 describe the ﬁ ndings of a phase 4, 
multicentre, open-label trial assessing non-inferiority 
of the eﬃ  cacy and safety of a ﬁ xed-dose formulation 
of artesunate–meﬂ oquine (developed by the Drugs 
for Neglected Diseases initiative and the Brazilian 
public health laboratory Farmanguinhos in 2002). This 
formulation has age-based, rather than weight-based 
dosing, facilitating its use in resource-poor settings. 
The once-daily dose is expected to promote adherence 
and to reduce the possibility of dosing errors. The 
comparator drug was artemether–lumefantrine, which is 
the ACT used most commonly in Africa.
With 944 participants from Tanzania, Burkina Faso, and 
Kenya, aged between 6·0 months and 59·8 months, this 
is the largest study assessing artesunate–meﬂ oquine in 
African children with uncomplicated falciparum malaria. 
The prolonged follow-up period of 63 days incorporated 
the long elimination half-life (2–3 weeks) of meﬂ oquine. 
In the per-protocol analysis, the PCR-corrected rate 
of adequate clinical and parasitological response 
at 63 days was 90·9% (370 of 407 patients) in the 
artesunate–meﬂ oquine group and 89·7% (365 of 
407 patients) in the artemether–lumefantrine group. 
Artesunate–meﬂ oquine was non-inferior to artemether–
lumefantrine (treatment diﬀ erence 1·23%, 95% CI 
–2·84% to 5·29%) and both parasite and fever clearance 
times were indistinguishable between groups after 
48 h, with some suggestion that initially rates were 
faster in the artesunate–meﬂ oquine group. There was 
no increase in microscopic gametocyte clearance rate 
with artesunate–meﬂ oquine and re-infection was 
delayed longer with artesunate–meﬂ oquine than with 
artemether–lumefantrine, as reported previously in a 
similar setting.9
The investigators found no diﬀ erence between 
treatment groups in the frequency of early vomiting 
(16% on any study day), and it reduced during the 
3-day course. This result accords with ﬁ ndings in 
other populations that vomiting is less frequent if the 
25 mg/kg dose of meﬂ oquine is divided evenly over the 
3 treatment days.6
Few neurological adverse events occurred in either 
treatment group. This ﬁ nding has to be put into context. 
As Sirima and colleagues note, the trial was not powered 
for speciﬁ c safety outcomes. During the long period 
of safety follow-up, 63 days, plus three more visits 
over 63 days after treatment failure, neuropsychiatric 
adverse event monitoring was encouraged, but it 
was not systematic. In children younger than 5 years, 
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standardised assessment of neuropsychiatric status is 
challenging, not least logistically, in a trial of this size.3,10 
Detailed assessment was done in young children (with 
mean age 3 years) in a single-arm study in Cameroon,5 
in which 3·8% of 213 children had a mild-to-moderate 
drug-related neuropsychiatric event after treatment 
with artesunate–meﬂ oquine, the most common of 
which was sleep disorder.
Reduced susceptibility to meﬂ oquine has been 
documented in African parasites, particularly in west 
Africa.11 Consistent surveillance of molecular resistance 
markers, in-vitro susceptibility, and in-vivo treatment 
responses will be important when monitoring the eﬀ ect 
of introducing the ﬁ xed-dose combination. Additional 
pharmacokinetic data from Africa could complement 
the current consensus that adjustment of the dose of 
meﬂ oquine in children is not necessary.4
Three issues merit operational consideration in the 
African setting of higher malaria transmission. First, 
there is an increased risk of neuropsychiatric eﬀ ects 
if the treatment course of artesunate–meﬂ oquine 
is repeated within 60 days.1,12 Indeed, Sirima and 
colleagues report that 444 (48%) of 933 children in 
their study were retreated with an alternative rescue 
treatment within 63 days, similar to proportions 
recorded by other investigators.13 The risk of repeated 
treatment should be investigated in well designed 
cohort studies;13 furthermore, awareness of this 
risk should be incorporated in training initiatives 
for health-care providers. Second, because of drug 
interaction,1 the eﬀ ects of previous meﬂ oquine 
exposure on the eﬃ  cacy of artemether–lumefantrine 
treatment should be assessed. Finally, comparison 
studies exploring cost-eﬀ ectiveness in African 
countries will be important.
Further complementary studies would optimise the 
safe delivery of a ﬁ xed-dose combination of artesunate-
meﬂ oquine to African children, but its increased 
availability could oﬀ er an eﬃ  cacious treatment with rapid 
action and prolonged protection from re-infection; an 
important resource in the ﬁ ght against malaria.
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A malaria vaccine in children with HIV
Plasmodium falciparum is the major cause of malaria 
cases and deaths globally, particularly in sub-Saharan 
Africa where HIV is also highly prevalent.1,2 The primary 
target population of a malaria vaccine is young 
children, and more than 2 million children in sub-
Saharan Africa are infected with HIV.2 Therefore, many 
HI V-infected children could beneﬁ t from a malaria 
vaccine, especially because HIV might increase the 
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